LQDA (Liquidia) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Liquidia Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Liquidia is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Liquidia's Risk Assessment

For the Biotechnology subindustry, Liquidia's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liquidia's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Liquidia's Risk Assessment falls into.

Liquidia (NAS:LQDA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Liquidia Risk Assessment Related Terms

Thank you for viewing the detailed overview of Liquidia's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

LT4:Germany

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Executives

Scott Moomaw	officer: SVP, Commercial	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta	officer: Chief Financial Officer	7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler	officer: General Counsel	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Jason Adair	officer: V.P. Crp Dvlpmnt and Strtgy	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Rajeev Saggar	officer: Chief Medical Officer	419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Roger Jeffs	director
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Caligan Partners Lp	director, 10 percent owner, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe	officer: Chief Operations Officer	C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Raman Singh	director	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Katherine Rielly-gauvin	director	419 DAVIS DRIVE, MORRISVILLE NC 27560
Stephen M Bloch	director	285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880
Joanna Horobin	director	215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142